p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation

Blood

Volumn 98, Issue 3, 2001, Pages 814-822

  Pettitt, Andrew R ^a,b   Sherrington, Paul D ^a,b   Stewart, Grant ^a,b   Cawley, John C ^a,b   Malcolm R Taylor, A ^a,b   Stankovic, Tatjana ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; ATM GENE; B CELL LEUKEMIA; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GROWTH REGULATION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; REGULATORY MECHANISM; TP53 GENE; TREATMENT OUTCOME;

EID: 0035437138     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.814     Document Type: Article

References (53)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052-1057.
2. Caligaris-Capio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17:399-408.
3. Lens D, Dyer M, Garcia-Marco JM, et al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol. 1997;99:848-857.
4. El Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993;82:3452-3459.
5. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148-3157.
6. Dohner H, Fischer C, Bentz M, et al. p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogues in chronic B-cell leukaemias. Blood. 1995;85:1580-1589.
7. Lane DP. p53, guardian of the genome. Nature. 1992;358:15-16.
8. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
9. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
10. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig R. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6301-6311.
11. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA-damaging agents. Oncogene. 1993;8:307-318.
12. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell. 1993;75:817-825.
13. Miyashita T, Reed J. Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
14. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
15. Lane DP. p53 and human cancers. Br Med Bull. 1994;50:582-599.
16. Prives C. How loops, β sheets, and α helices help us to understand p53. Cell. 1994;78:543-546.
17. Newcombe EW. p53 gene mutations in lymphoid disease and their possible relevance to drug resistance. Leuk Lymphoma. 1995;17:211-221.
18. Anastasi J, Le Beau MM, Vardiman JW, et al. Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. Blood. 1992;79:1796-1801.
19. Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89:2516-2522.
20. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358:80-83.
21. Watanabe T, Hotta T, Kinoshita T, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood. 1994;84:3158-3165.
22. Bues-Ramos CE, Manshouri T, Haidar MA, Huh YO, Keating MJ, Albitar M. Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk Lymphoma. 1995;17:13-18.
23. Hjalmar V, Kimby E, Christensson B. B-cell chronic lymphocytic leukemia: association between the MDM2 and p53 protein expression and trisomy 12 [abstract]. Blood. 1999;94:546.
24. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 1998;95:5-8.
25. Taylor AMR. What has the cloning of the ATM gene told us about ataxia telangiectasia? Int J Radiol Biol. 1998;73:365-371.
26. Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet. 1998;20:398-400.
27. Waterman MJF, Stravridi ES, Waterman JLF, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet. 1998;19:175-178.
28. Starostik P, Manshouri T, O'Brien S, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4552-4557.
29. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353:26-29.
30. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood. 1999;94:748-753.
31. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 1999;59:24-27.
32. Barlow C, Brown KD, Deng C-X, et al. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet. 1997;17:453-456.
33. Westphal CH, Rowan S, Schmaltz C, Elson A, Fisher DE, Leder P. Atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat Genet. 1997;16:397-401.
34. Khanna KK, Lavin MF. Ionising radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene. 1993;8:3307-3312.
35. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-126.
36. Midgeley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends on cell type in vivo. J Cell Sci. 1995;108:1943-1848.
37. Folkman J, Moscona A. Role of cell shape in growth control. Nature. 1978;273:345-349.
38. Zhan Q, Carrier F, Fornace JR. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol. 1993;13:4242-4250.
39. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. "Touchdown" PCR to circumvent spurious priming during gene amplification [abstract]. Nucleic Acids Res. 1991;19:4008.
40. Harris RJ, Pettitt AR, Schmutz C, et al. Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes. J Immunol. 2000;164:3887-3893.
41. Liu Q, Sommer SS. Restriction endonuclease fingerprinting (REF): a sensitive method for screening in long contiguous segments of DNA. Biol Tech. 1995;18:470-477.
42. Vorechovsky I, Rasio D, Luo L, et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res. 1996;56:2726-2732.
43. Ormerod MG. The study of apoptotic cells by flow cytometry. Leukemia. 1998;12:1013-1025.
44. Forbes IJ, Zalewski PD, Giannakis C, Cowled PA. Induction of apoptosis in chronic lymphocytic leukemia cells and its prevenetion by phorbol ester. Exp Cell Res. 1992;198:367-372.
45. Wyllie AH, Morris RG. Hormone-induced cell death: purification and properties of thymocytes undergoing apoptosis after glucocorticoid treatment. Am J Pathol. 1982;109:78-87.
46. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53:3976-3985.
47. Reed JC. Molecular biology of chronic lymphocytic leukaemia. Semin Oncol. 1998;25:11-18.
48. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847-849.
49. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849-852.
50. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-526.
51. Zhou B-BS, Elledge SJ. The DNA damage response: putting checkpoints in prospective. Nature. 2000;408:433-439.
52. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxiclty of anticancer agents. Cell. 1993;74:957-967.
53. Milner J, Metcalf EA. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell. 1991;65:765-774.